Biofrontera Disclosed Failure to Satisfy a Continued Listing Rule or Standard

Detailed summary
On November 16, 2026, Biofrontera received notice that its common stock was below Nasdaq's $1.00 minimum bid price for 30 consecutive business days, violating Nasdaq Listing Rule…
On November 16, 2026, Biofrontera received notice that its common stock was below Nasdaq's $1.00 minimum bid price for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). The notice has no immediate effect on trading, and the company has until May 17, 2027, to regain compliance by meeting the minimum bid price for at least 10 consecutive business days. If it does not, it may qualify for an additional compliance period; delisting is possible if it fails to meet Nasdaq's requirements.
Opening of the article, excerpted from TradingView. To read the rest, open the article on the publisher's site.
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.tradingview.com)




